Avidity Biosciences, Inc. (RNA) - Earnings growth forecast for next year
Avidity Biosciences (RNA) is protected by unique patents in the elite genetics segment, which prevents the replication of its technologies. The company's revolutionary RNA drugs target the root causes of muscle pathologies, demonstrating potential for a commercial breakout. Business flexibility is ensured through the full outsourcing of production and trials. The consensus forecast for forward EPS growth captures market shifts, where -50.40 indicates the level of this metric.
Analytical breakdowns for Avidity Biosciences
- share price and consensus valuation forecast:
- market capitalization indicators:
- book capitalization indicators:
- debt and liquidity data:
Total Debt to Capital Avidity Biosciences|RNA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Avidity Biosciences, Inc.|RNA - Company Total Debt Obligations|Debts to Book Capitalization Avidity Biosciences|RNA - Long-Term Debt|Company Short-Term Debt Avidity Biosciences|Quick Ratio aviditybiosciences.com
- net income and valuation ratios data:
RNA - Net Income|Projected Future Earnings Avidity Biosciences|RNA - Market Cap to Earnings|Future Price to Earnings Avidity Biosciences|RNA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avidity Biosciences|RNA - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Avidity Biosciences|RNA - Earnings per share for the last 12 months|Quarterly EPS earnings growth aviditybiosciences.com|RNA - Earnings growth in current year|Earnings growth forecast for next year Avidity Biosciences
Initial company analysis:Avidity, RNA
To minimize fundamental risks, investors should select assets with an upward trend in expected earnings, where the metric measures the percentage change in projected EPS for the coming year relative to the current one. In the case of Avidity Biosciences (RNA), current expectations for the EPS n+1 growth rate reflect the market's real-time assessment of the efficiency of specialized cold chains, which guarantee the preservation of biomaterials and stable business margins.
Competitors of Avidity Biosciences
TEM (Tempus AI, Inc) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year QGEN|Earnings growth forecast for next year IONS|Consensus forecast of earnings per share growth for next year repligen.com|Net earnings per share growth forecast for next year CRISPR Therapeutics CRSP|GeneDx Holdings (WGS) - Expected net earnings per share growth next year|RARE - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Beam Tx BEAM|SRPT: Earnings growth forecast for next year|Expected earnings per share growth for next year twistbioscience.com|TXG (10x Genomics) - Earnings growth forecast for next year|Intellia Therapeutics Inc (NTLA) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year STOK|BLFS - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Wave Life Sciences WVE|MAZE: Projected earnings per share growth rate for next year|Sionna Therapeutics - Earnings growth forecast for next year|Prime Medicine Inc (PRME) - Expected earnings per share growth for next year|TSHA: Earnings growth forecast for next year|Expected net earnings per share growth next year uniQure Pharma (QURE)|Net earnings per share growth forecast for next year MeiraGTx Holdings plc|regenxbio.com (RGNX) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Solid Biosciences (SLDB)|OCGN (Ocugen Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Pacific Biosciences of California PACB|BNTC: Projected earnings per share growth rate for next year|Design Therapeutics - Earnings growth forecast for next year|RCKT - Earnings growth forecast for next year|FDMT: Earnings growth forecast for next year|Projected earnings per share growth rate for next year LXEO|Net earnings per share growth forecast for next year Korro Bio Inc.|Projected earnings per share growth rate for next year EDIT (Editas Corp)|Earnings growth forecast for next year SLN|Earnings growth forecast for next year proqr.com (PRQR)|Earnings growth forecast for next year CDXS (Codexis)|Earnings growth forecast for next year Sangamo Therapeutics Inc. SGMO|NAUT: Expected earnings per share growth for next year|MGX: Net earnings per share growth forecast for next year|DTIL: Earnings growth forecast for next year|GBIO - Consensus forecast of earnings per share growth for next year|BOLD (Boundless Bio) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year XCUR (Exicure Corp)|Earnings growth forecast for next year IMNN|Consensus forecast of earnings per share growth for next year phiopharma.com|Mustang Bio - Expected earnings per share growth for next year|Projected earnings per share increase next year RNAZ (TransCode Therapeutics Inc.)|BNGO: Expected earnings per share growth for next year|Expected net earnings per share growth next year Applied DNA Sciences Inc|BLUE (Bluebird Bio) - Expected earnings per share growth for next year|ImmunoPrecise Antibodies Ltd. - Expected earnings per share trend next year|OMGA (Omega Therapeutics) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year OMIC|Earnings growth forecast for next year RGLS|Consensus forecast of earnings per share growth for next year Syros Pharmaceuticals Inc.|Net earnings per share growth forecast for next year Codex DNA TBIO|TRACON Pharmaceuticals, Inc (TCON) - Expected net earnings per share growth next year|UBX - Net earnings per share growth forecast for next year
